Bone Fracture - Pipeline Review, H1 2018

Publication ID:
GMD0318042

Publication Date:
March 13, 2018

Pages:
105

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
○ Single User License (PDF), $2,000.00
○ Site License (PDF), $4,000.00
○ Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart

Description:
Bone Fracture - Pipeline Review, H1 2018
Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and
industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Fracture - Overview
Bone Fracture - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture - Companies Involved in Therapeutics Development
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Pluristem Therapeutics Inc
TissueGene Inc
Viking Therapeutics Inc
Bone Fracture - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OsteoStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pralatide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-008399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells
Sep 26, 2017: Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA
delayed-union study interim analysis

Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study

Sep 05, 2017: Pluristem Therapeutics: $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program

Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bone Fracture, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2018

Bone Fracture - Pipeline by BiologicsMD Inc, H1 2018

Bone Fracture - Pipeline by Biopharm GmbH, H1 2018

Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2018

Bone Fracture - Pipeline by Cellmid Ltd, H1 2018
Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018
Bone Fracture - Pipeline by Entera Bio Ltd, H1 2018
Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by ethris GmbH, H1 2018
Bone Fracture - Pipeline by Hemostemix Inc, H1 2018
Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2018
Bone Fracture - Pipeline by Laboratorios SALVAT SA, H1 2018
Bone Fracture - Pipeline by Novartis AG, H1 2018
Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2018
Bone Fracture - Pipeline by TissueGene Inc, H1 2018
Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2018
Bone Fracture - Dormant Projects, H1 2018
Bone Fracture - Dormant Projects, H1 2018 (Contd..1), H1 2018
Bone Fracture - Discontinued Products, H1 2018

List of Figures
List of Figures
Number of Products under Development for Bone Fracture, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Companies Mentioned:
American Gene Technologies International Inc
BiologicsMD Inc
Biopharm GmbH
Bone Therapeutics SA
Cellmid Ltd
Chrysalis BioTherapeutics Inc
Entera Bio Ltd
Escape Therapeutics Inc
ethris GmbH
Hemostemix Inc
Kuros Biosciences AG
License Types:

Single User License (PDF)

• This license allows for use of a publication by one person.
• This person may print out a single copy of the publication.
• This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
• This person cannot share the publication (or any information contained therein) with any other person or persons.
• Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

• This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
• These users may print out a single copy of the publication.
• These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
• These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
• Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

• This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
• Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or
persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

---

**NAVIGATE**

About Us
Reports by Region
FAQ
Privacy Policy
TERMS & CONDITIONS
CONTACT

---

**RECENT POSTS**

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10